

Journalbeiträge

1. Basecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B, Schmitz N, Trümper L, Griesinger F (2008) Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. *BRIT J DERMATOL*, 141(1): 52-9.
2. Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, Ott G, Banham AH, Berger H, Feller AC, Hansmann ML, Hasenclever D, Hummel M, Lenze D, Möller P, Stuerzenhofecker B, Loeffler M, Truemper L, Stein H, Siebert R, Spang R (2008) Pathway activation patterns in diffuse large B-cell lymphomas. *LEUKEMIA*, 22(9): 1746-54.
3. Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschmeyer L, Kreuz M, Truemper L, Landt O, Menzel A, Pfreundschuh M, Roemer K (2008) MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. *BMC CANCER*, 8: 116.
4. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, Schweyer S, Kosari F, Klapper W, Truemper L, Wulf GG (2008) Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. *LEUKEMIA*, 22(8): 1576-86.
5. Dierlamm J, Murga Penas EM, Bentink S, Wessendorf S, Berger H, Hummel M, Klapper W, Lenze D, Rosenwald A, Haralambieva E, Ott G, Cogliatti SB, Möller P, Schwaenen C, Stein H, Löffler M, Spang R, Trümper L, Siebert R, Deutsche KNP"MiML (2008) Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. *HAEMATOL-HEMATOL J*, 93(5): 688-96.
6. Gleissner B, Küppers R, Siebert R, Glass B, Trümper L, Hiddemann W, Dreyling M (2008) Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profiling. *BRIT J DERMATOL*, 142(2): 166-78.
7. Haase D (2008) Cytogenetic features in myelodysplastic syndromes. *ANN HEMATOL*, 87(7): 515-26.
8. Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, Jung W, Trümper L, Glass B (2008) Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors. *SCAND J IMMUNOL*, 67(3): 218-29.
9. Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Stocking C, Bäsecke J (2008) Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. *ONCOGENE*, 27(29): 4096-106.
10. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluijn-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M, Low Grade Lymphoma Study Group (GLSG) G, European MCLN (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *BLOOD*, 111(2): 558-65.
11. Jung W, Trümper L (2008) [Differential diagnosis and diagnostic strategies of lymphadenopathy.]. *INTERNIST*, 49(3): 305-320.
12. Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B, Haase D, Siebert R, Ghadimi BM, Neumann C, Emmert S (2008) Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells. *ARCH DERMATOL*, 144(3): 361-4.
13. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, Loeffler M, Trümper L, Pfreundschuh M, Siebert R (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *LEUKEMIA*, 22(12): 2226-9.
14. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, Schwaenen C, Wessendorf S, Spang R, Möller P, Hansmann ML, Bernd HW, Ott G, Hummel M, Stein H, Loeffler M, Trümper L, Zimmermann M, Reiter A, Siebert R (2008) Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. *BLOOD*, 112(4): 1374-81.
15. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Klöss M, Gocht D, Potthoff B, Tzvetkov M, Brockmöller J, Löffler M, Pfreundschuh M, Trümper L (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. *CLIN CANCER RES*, 14(12): 3777-84.
16. Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Brockmöller J, Kaiser R (2008) Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. *CLIN PHARMACOL THER*, 83(5): 749-57.
17. Lörinczi E, Napp J, Contreras-Jurado C, Pardo LA, Stühmer W (2008) The voltage dependence of hEag currents is not determined solely by membrane-spanning domains. *EUR BIOPHYS J BIOPHY*, -: -.
18. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong EWT, Steelman LS, Bäsecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahon M, Evangelisti C, Martelli AM (2008) Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. *LEUKEMIA*, 22(11): 2080-90.
19. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM (2008) Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. *LEUKEMIA*, 22(4): 708-22.
20. McCubrey JA, Sokolovsky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS (2008) Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. *Adv Enzyme Regul*, 48: 113-35.
21. McCubrey JA, Bäsecke J, Cervello M, Martelli AM, Franklin RA (2008) GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. *CANCER BIOL THER*, 7(7): 1079.
22. Missbach-Guentner J, Dullin C, Kimmina S, Zientkowska M, Domeyer-Missbach M, Malz C, Grabbe E, Stühmer W, Alves F (2008) Morphologic changes of mammary carcinomas in mice over time as monitored by flat-panel detector volume computed tomography. *NEOPLASIA*, 10(7): 663-73.
23. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) G (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *LANCET ONCOL*, 9(2): 105-16.
24. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, Vrieling T, Mesters R, Mergenthaler HG, Einsele H, Bentz M, Lengfelder E, Trümper L, Rube C, Schmitz N, Loeffler M, High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) G (2008) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). *ANN ONCOL*, 19(3): 545-52.

Abteilung "Hämatologie und Onkologie"

25. Ponce ML, Koelling S, Kluever A, Heinemann DE, Miosge N, Wulf G, Frosch KH, Schütze N, Hufner M, Siggelkow H (2008) Coexpression of osteogenic and adipogenic differentiation markers in selected subpopulations of primary human mesenchymal progenitor cells. *J CELL BIOCHEM*, 104(4): 1342-55.
26. Pukrop T, Binder C (2008) The complex pathways of Wnt 5a in cancer progression. *J MOL MED-JMM*, 86(3): 259-66.
27. Rüchel R, Binder C (2008) [Immune reconstitution inflammatory syndrome (IRIS): danger at the end of high risk]. *MYCOSES*, 51 Suppl 3: 20-1.
28. Schroeter MR, Leifheit M, Sudholt P, Heida NM, Dellas C, Rohm I, Alves F, Zientkowska M, Rafail S, Puls M, Hasenfuss G, Konstantinides S, Schäfer K (2008) Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. *CIRC RES*, 103(5): 536-44.
29. Schüler A, Schwieger M, Engelmann A, Weber K, Horn S, Müller U, Arnold MA, Olson EN, Stocking C (2008) The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. *BLOOD*, 111(9): 4532-41.
30. Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA (2008) Akt as a therapeutic target in cancer. *Expert Opin Ther Targets*, 12(9): 1139-65.
31. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA (2008) Contributions of the Raf/MEK/ERK, PI3K/PEN/Akt/mTOR and Jak/STAT pathways to leukemia. *LEUKEMIA*, 22(4): 686-707.
32. Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F (2008) Duocarmycin-based prodrugs for cancer prodrug monotherapy. *BIOORGAN MED CHEM*, 16(12): 6312-8.
33. Tietze LF, von Hof JM, Krewer B, Müller M, Major F, Schuster HJ, Schuberth I, Alves F (2008) Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy. *CHEMMEDCHEM*, 3(12): 1946-55.
34. Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M, High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) G (2008) Dose-escalated CHOP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. *ANN ONCOL*, 19(3): 538-44.
35. Vockerodt M, Morgan SL, Kuo M, Wei W, Chukwuma MB, Arrand JR, Kube D, Gordon J, Young LS, Woodman CB, Murray PG (2008) The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. *J PATHOL*, 216(1): 83-92.
36. Ziepert M, Schmits R, Trümper L, Pfreundschuh M, Loeffler M, High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) G (2008) Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. *ANN ONCOL*, 19(4): 752-62.

Buchbeiträge

1. Trümper L (2008) Aggressive B- und T-Zell-Lymphome. In: Preiß, Dornhoff, Hagmann, Schmieder (Hg.) Taschenbuch Onkologie Interdisziplinäre Empfehlungen zur Therapie 2008 / 2009. Zuckschwerdt Verlag, München, 21-30.

Habilitationen

1. Bäsecke J, Leukämogenetische Relevanz AML-assoziiertes gebetischer Aberrationen. Habilitation Universität Göttingen 2008.

Medizinische Dissertationen

1. Berger L, Dr. med., Untersuchungen zur Häufigkeit einer Translokation (9;22)(p24;q11) bei Patienten mit AML, ALL und CML. Dissertation Universität Göttingen 2008.
2. Bleckmann A, Dr. med., Struktur-Aktivitäts-Relationen kleiner Moleküle am Beispiel von Epothilon und mGluR5-Modulatoren. Dissertation Universität Göttingen 2008.
3. Corsham S, Dr. med., Expression des ABC-Transporters ABCA3 in Zellen der physiologischen Hämatopoese und in maligne transformierten lymphatischen Zellen. Dissertation Universität Göttingen 2008.
4. Cremer E, Dr. med., DNS-Reparatur und Stimulierbarkeit durch G-CSF: Untersuchungen zweier potenzieller Pathomechanismen bei myelodysplastischen Syndromen und akuter myeloischer Leukämie. Dissertation Universität Göttingen 2008.
5. Gosselke J, Dr. med., Nachweis der Trisomie 12 in CD34+-Zellen bei Patienten mit chronischer lymphatischer Leukämie der B-Zellreihe (B-CLL). Dissertation Universität Göttingen 2008.
6. Günther S, Dr. med., Identifikation Discoidin-Domänen-Rezeptor-1-abhängig regulierter Gene in SCID-Maustumoren. Dissertation Universität Göttingen 2008.
7. Jung H, Dr. med., Wirkung einer Amifostin-Langzeittherapie auf Hämatopoese und Krankheitsverlauf bei Patienten mit myelodysplastischem Syndrom (MDS) (eine klinische Phase-III-Studie). Dissertation Universität Göttingen 2008.
8. Matern J, Dr. med., Vergleich der Wirkung zweier Infusionsschemata von Desmopressin auf die Normalisierung des in-vitro-Blutungsvolumens von mit Acetylsalicylsäure vorbehandelten Probanden. Dissertation Universität Göttingen 2008.
9. Scharnberg P, Dr. med., Reverse-Transkription-Polymerasekettenreaktion (RT-PCR) zum Nachweis von Parathormon-ähnlichem Protein (PTHrP) sowie Immunzytologie von Zytokeratin 18 (CK 18) zur Detektion disseminierter Tumorzellen im peripheren Blut und Knochenmark von Patientinnen mit. Dissertation Universität Göttingen 2008.

Naturwiss. u.a. nichtmed. Diss.

1. Kube D, Schoof N, Dr. rer. nat., Onkogenomische Aspekte Zytokin-assoziiertes Signaltransduktion. Dissertation Universität Göttingen 2008.

Abteilung "Hämatologie und Onkologie"

Diplomarbeiten

1. Herz C, Dipl.-Biol., Kooperation des intrazellulären ABC-Transporters A3 Kooperationen des intrazellulären ABC-Transporters A3 mit plasmamembranären Transportern in der Entwicklung eines Multidrogenresistenzphänotyps (MDR) eines Multidrogenresistenzphänotyps (MDR). Diplomarbeit Universität Göttingen 2008.

Masterarbeiten

1. Mathejczyk J (2008) In vivo monitoring of angiogenesis in tumour models by flat-panel volume computed tomography and near-infrared optical imaging. Universität Göttingen, MSc.